Table 4.
End of eight weeks comparison of analytes between Tocovid and placebo groups.
| Analyte | Placebo (n = 39) | Tocovid (n = 38) | p-Value |
|---|---|---|---|
| Serum Biomarkers | |||
| NGF (ng/mL) a | 10.02 ± 2.28 | 11.04 ± 2.05 | 0.047 * |
| MDA (ng/mL) b | 1158.37 (794.77) | 959.57 (903.02) | 0.551 |
| VCAM-1 (ng/mL) a | 257.40 ± 113.23 | 278.28 ± 129.36 | 0.453 |
| TNFR-1 (pg/mL) b | 23.24 (55.52) | 21.88 (45.43) | 0.874 |
| TXB2 (pg/mL) b | 162.57 (164.41) | 150.70 (132.24) | 0.418 |
| HbA1c (%) a | 7.81 ± 1.29 | 7.43 ± 1.11 | 0.174 |
| SBP (mmHg) a | 129.00 ± 13.95 | 133.16 ± 14.70 | 0.207 |
| DBP (mmHg) b | 75.00 (14.00) | 73.00 (16.00) | 0.386 |
| BMI (kg/m2) a | 27.81 ± 4.89 | 27.57 ± 4.29 | 0.823 |
| α-Tocopherol (µmol/L) | 37.90 ± 17.61 | 67.10 ± 38.59 | <0.001 * |
| Safety Tests | |||
| eGFR b | 62.00 (39.00) | 63.50 (42.00) | 0.303 |
| Urea a | 6.90 ± 2.61 | 6.63 ± 2.47 | 0.651 |
| AST b | 19.00 (8.00) | 18.50 (8.25) | 0.394 |
| ALT b | 20.00 (12.00) | 19.00 (14.00) | 0.298 |
| TC a | 4.43 ± 1.10 | 4.95 ± 1.03 | 0.036 * |
| HDL-C b | 1.20 (0.30) | 1.30 (0.50) | 0.569 |
n: Number of participants in subgroup; NGF: Nerve growth factor; MDA: Malondialdehyde; VCAM-1: Vascular cell adhesion molecule-1; TNFR-1: Tumor necrosis factor receptor-1; TXB2: Thromboxane B2; HbA1c: Hemoglobin A1c; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: Body mass index; α-Tocopherol: Corrected serum α-tocopherol levels; eGFR (ml/min/1.73 m2): Estimated glomerular filtration rate; Urea (mmol/L); AST (U/L): Aspartate transaminase; ALT (U/L): Alanine transaminase; TC (mmol/L): Total cholesterol; HDL-C (mmol/L): High-density lipoprotein cholesterol. * Data are significant if p < 0.05. a Data presented as mean ± standard deviation; p-value obtained using independent t-test, assumptions were fulfilled. b Data presented as median (interquartile range); p-value obtained using Mann–Whitney U test.